Stock 4519 CHUGAI PHARMACEUTICAL CO., LTD.
Add to a list

ETFs Chugai Pharmaceutical Co., Ltd.

Equities

4519

JP3519400000

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 06:30:00 13/01/2026 GMT 		5-day change 1st Jan Change
8,437.00 JPY +0.19% Intraday chart for Chugai Pharmaceutical Co., Ltd. -0.93% +2.35%
12-30 Chugai Completes Merger With Renalys Pharma MT
12-29 Chugai Pharmaceutical Co., Ltd. completed the acquisition of Renalys Pharma. CI

ETFs positioned on Chugai Pharmaceutical Co., Ltd.

Name Varia. Jan 1. Weight AuM
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY
+4.14%6.57% 27 M€
NOMURA NEXT FUNDS MSCI JAPAN EMPOWERING WOMEN SELECT INDEX ETF - JPY ETF Nomura NEXT FUNDS MSCI Japan Empowering Women Select Index ETF - JPY
+5.60%1.87% 68 M€
DAIWA ETF MSCI JAPAN EMPOWERING WOMEN INDEX ETF - JPY ETF Daiwa ETF MSCI Japan Empowering Women Index ETF - JPY
+4.70%1.59% 5 M€
NOMURA NIKKEI 225 EXCHANGE TRADED FUND ETF - JPY ETF Nomura Nikkei 225 Exchange Traded Fund ETF - JPY
+6.35%1.53% 79,646 M€
DAIWA ETF-NIKKEI 225 ETF - JPY ETF Daiwa ETF-Nikkei 225 ETF - JPY
+6.38%1.32% 35,861 M€
SMDAM NIKKEI225 ETF - JPY ETF SMDAM NIKKEI225 ETF - JPY
+6.54%1.31% 1,038 M€
GLOBAL X MSCI GOVERNANCE-QUALITY JAPAN ETF - JPY ETF Global X MSCI Governance-Quality Japan ETF - JPY
+6.14%1.28% 10 M€
MAXIS NIKKEI 225 ETF - JPY ETF MAXIS Nikkei 225 ETF - JPY
+6.28%1.22% 18,216 M€
NEXT FUNDS MSCI JAPAN COUNTRY ESG LEADERS INDEX EXCHANGE TRADED FUND - JPY ETF NEXT FUNDS MSCI Japan Country ESG Leaders Index Exchange Traded Fund - JPY
+5.45%1.13% 12 M€
NEXT FUNDS SOLACTIVE JAPAN ESG CORE INDEX ETF - JPY ETF NEXT FUNDS Solactive Japan ESG Core Index ETF - JPY
-30.99%1.11% 4 M€
LYXOR MSCI JAPAN ESG LEADERS EXTRA (DR) UCITS ETF - ACC - EUR ETF Lyxor MSCI Japan ESG Leaders Extra (DR) UCITS ETF - Acc - EUR
-.--%1.09% 0 M€
LYXOR MSCI JAPAN ESG LEADERS EXTRA (DR) UCITS ETF - DAILY HEDGED TO EUR - ACC - EUR ETF Lyxor MSCI Japan ESG Leaders Extra (DR) UCITS ETF - Daily Hedged to EUR - Acc - EUR
-.--%1.09% 0 M€
NOMURA NIKKEI 300 INDEX EXCHANGE TRADED FUND ETF - JPY ETF Nomura Nikkei 300 Index Exchange Traded Fund ETF - JPY
+1.31%1.08% 19 M€
DAIWA ETF MSCI JAPAN ESG SELECT LEADERS INDEX ETF - JPY ETF Daiwa ETF MSCI Japan ESG Select Leaders Index ETF - JPY
+4.67%0.77% 78 M€
NOMURA NEXT FUNDS NOMURA ENTERPRISE VALUE ALLOCATION INDEX ETF - JPY ETF Nomura NEXT FUNDS Nomura Enterprise Value Allocation Index ETF - JPY
+5.57%0.7% 77 M€
LEVERAGE SHARES PUBLIC LIMITED COMPANY - 3X LONG JAPAN ETP ETF Leverage Shares Public Limited Company - 3x Long Japan ETP
+13.97%0.55% 1 M€
LEVERAGE SHARES PUBLIC LIMITED COMPANY - LS -3X SHORT JAPAN ETP ETF Leverage Shares Public Limited Company - LS -3x Short Japan ETP
-.--%0.55% 0 M€
DAIWA ETF FTSE BLOSSOM JAPAN INDEX ETF - JPY ETF Daiwa ETF FTSE Blossom Japan Index ETF - JPY
+4.28%0.54% 16 M€
NOMURA NEXT FUNDS JPX-NIKKEI INDEX 400 ETF - JPY ETF Nomura NEXT FUNDS JPX-Nikkei Index 400 ETF - JPY
+5.54%0.51% 10,968 M€
MAXIS JPX-NIKKEI 400 ETF - JPY ETF MAXIS JPX-Nikkei 400 ETF - JPY
+5.71%0.51% 5,676 M€
CSIF (IE) MSCI WORLD ESG LEADERS MINIMUM VOLATILITY BLUE UCITS ETF B - USD ETF CSIF (IE) MSCI World ESG Leaders Minimum Volatility Blue UCITS ETF B - USD
-.--%0.49% 0 M€
NZAM ETF TOPIX EX-FINANCIALS - JPY ETF NZAM ETF TOPIX Ex-Financials - JPY
+3.22%0.44% 20 M€
MAXIS TOPIX ETF - JPY ETF MAXIS TOPIX ETF - JPY
+5.61%0.37% 23,777 M€
DAIWA ETF TOPIX ETF - JPY ETF Daiwa ETF TOPIX ETF - JPY
+5.65%0.37% 72,478 M€
NOMURA TOPIX EXCHANGE TRADED FUND ETF - JPY ETF Nomura TOPIX Exchange Traded Fund ETF - JPY
+5.48%0.37% 160,441 M€
VANECK WORLD EQUAL WEIGHT SCREENED UCITS ETF - EUR ETF VanEck World Equal Weight Screened UCITS ETF - EUR
+3.05%0.35% 1,101 M€
VANECK MULTI-ASSET CONSERVATIVE ALLOCATION UCITS ETF - EUR ETF VanEck Multi-Asset Conservative Allocation UCITS ETF - EUR
+2.27%0.14% 20 M€
12

Company Profile

Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,026
Sector
Pharmaceuticals
Calendar
01-14 - J.P. Morgan Healthcare Conference
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI
AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
8,437.00JPY
Average target price
8,764.29JPY
Spread / Average Target
+3.88%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 4519 Stock
  4. ETFs Chugai Pharmaceutical Co., Ltd.

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition